Comparison of automated nucleic acid extraction methods for the detection of cytomegalovirus DNA in fluids and tissues by Jesse J. Waggoner & Benjamin A. Pinsky
Submitted 27 December 2013
Accepted 16 March 2014
Published 8 April 2014
Corresponding author
Benjamin A. Pinsky,
bpinsky@stanford.edu
Academic editor
Siouxsie Wiles
Additional Information and
Declarations can be found on
page 8
DOI 10.7717/peerj.334
Copyright
2014 Waggoner and Pinsky
Distributed under
Creative Commons CC-BY 3.0
OPEN ACCESS
Comparison of automated nucleic acid
extraction methods for the detection of
cytomegalovirus DNA in fluids and
tissues
Jesse J. Waggoner
1 and Benjamin A. Pinsky
1,2
1 Department of Medicine, Division of Infectious Diseases and Geographic Medicine,
Stanford University School of Medicine, Stanford, CA, USA
2 Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
ABSTRACT
Testing for cytomegalovirus (CMV) DNA is increasingly being used for specimen
types other than plasma or whole blood. However, few studies have investigated
the performance of different nucleic acid extraction protocols in such specimens.
In this study, CMV extraction using the Cell-free 1000 and Pathogen Complex 400
protocolsontheQIAsymphonySampleProcessing(SP)systemwerecomparedusing
bronchoalveolar lavage fluid (BAL), tissue samples, and urine. The QIAsympho-
nyAssay Set-up (AS) system was used to assemble reactions using artus CMV PCR
reagents and amplification was carried out on the Rotor-Gene Q. Samples from 93
patients previously tested for CMV DNA and negative samples spiked with CMV
AD-169 were used to evaluate assay performance. The Pathogen Complex 400 pro-
tocol yielded the following results: BAL, sensitivity 100% (33/33), specificity 87%
(20/23);tissue,sensitivity100%(25/25),specificity100%(20/20);urine,sensitivity
100% (21/21), specificity 100% (20/20). Cell-free 1000 extraction gave comparable
results for BAL and tissue, however, for urine, the sensitivity was 86% (18/21) and
specimen quantitation was inaccurate. Comparative studies of different extraction
protocolsandDNAdetectionmethodsinbodyfluidsandtissuesareneeded,asassays
optimized for blood or plasma will not necessarily perform well on other specimen
types.
Subjects Infectious Diseases, Pathology
Keywords Cytomegalovirus, Laboratory medicine, Clinical virology
INTRODUCTION
Cytomegalovirus (CMV) is a common human viral pathogen with anywhere from
45%–100% of adults demonstrating serologic evidence of CMV exposure, depending on
the population (Cannon, Schmid & Hyde, 2010). CMV infection remains an important
cause of morbidity and mortality following solid organ and hematopoietic stem cell
transplantation (Kotton et al., 2010; Ljungman et al., 2008). CMV disease has also been
showntopredicttreatmentfailureinulcerativecolitis(UC),anditcancausesensorineural
hearing loss and developmental abnormalities in congenitally infected neonates, even
whenasymptomaticatbirth(Lanarietal.,2006;Roblinetal.,2011).
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the standard of care for detection and monitoring in transplant recipients (Caliendo
et al., 2007; Kotton et al., 2010). The definitive diagnosis of CMV end-organ disease
in immunocompromised patients often requires demonstration of characteristic viral
inclusions or detection of viral proteins by immunohistochemical staining in tissue
samples. However, PCR testing for CMV DNA in body fluids and tissues is increasingly
being used to aid in the diagnostic work-up for entities such as CMV pneumonitis in
lungtransplantrecipientsorcolonicinvolvementinUC(Ljungman,Griffiths&Paya,2002;
Riise et al., 2000; Roblin et al., 2011). In the case of congenital CMV infection, diagnosis
is usually made by detection of the virus in urine or saliva, although prenatal testing
using amniotic fluid samples in quantitative PCR or RT-PCR assays has been described
(Goegebueretal.,2009;Lanarietal.,2006;Revelloetal.,2003).
A number of comparative analyses of methods for CMV DNA detection and quanti-
tation in plasma have been published, but similar evaluations of the detection of CMV
DNA in non-plasma specimens are limited (Bravo et al., 2011; Caliendo et al., 2007; Fahle
& Fischer, 2000; Forman, Wilson & Valsamakis, 2011). Furthermore, it is unclear if the
same nucleic acid extraction protocol used to isolate CMV DNA from plasma will be the
optimum for non-plasma samples (Fahle & Fischer, 2000; Tang et al., 2005; Verheyen et al.,
2012). In this study, we describe the performance characteristics of the artus CMV PCR
for the qualitative detection of CMV DNA in patient bronchoalveolar lavage (BAL) fluid,
tissue samples, and urine using two automated extraction protocols, the Cell-free 1000
and Pathogen Complex 400, on the QIAsymphony Sample Processing (SP)/Assay Set-up
(AS) system and Rotor-Gene Q (RGQ). The Cell-free 1000 protocol is a plasma extraction
protocol, whereas the Pathogen Complex 400 was designed for use with serum, plasma,
CSF, respiratory specimens (including BAL fluid), and urine. These results are compared
with those obtained using a previous laboratory standard, the COBAS Amplicor CMV
Monitor(CACM)assayfollowingextractionwiththeMagNAPureLCDNAisolationkit.
MATERIALS AND METHODS
Specimens
TheStanfordUniversityInstitutionalReviewBoardwaivedapprovalforthisworkasitwas
performedintheclinicalvirologylaboratoryforthepurposesofqualityassuranceandtest
validation.
Ninety-three archived patient specimens, previously tested using the CACM assay
(Roche, Indianapolis, IN), were evaluated. Samples were stored as aliquots at −80 ◦C
following initial testing. These specimens included 36 BAL (13 detected, 23 not detected),
25 tissues [5 detected (3 small bowel, 2 colon), 20 not detected (5 skin, 4 small bowel,
4 colon, 3 liver, 2 lung, 1 lymph node, 1 anterior mediastinal mass], and 21 urine samples
(1 detected, 20 not detected). BAL specimens were collected in sterile containers, and if
mucoid, the samples were vortexed with sterile glass beads to reduce specimen viscosity.
Tissue specimens were collected in M4RT (Remel, Lenexa, KS) viral transport media
(VTM) or sent in a sterile container, and upon receipt, transferred to Bartels Tissue
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with 2% fetal bovine serum, 15 µg/ml gentamicin, 100 µg/ml vancomycin, and 3.5 µg/ml
amphotericin B. Tissues were minced using a sterile scalpel and then ground with a tissue
grinder.
Quantitated cell culture lysate, obtained from fibroblast cells infected with the AD-169
strainofCMV(ATCCVR-538),wasusedtospikenegativesamplesforextractionusingthe
differentprotocols.CellculturelysatewasquantitatedusingtheartusCMVPCR.ForBAL
and tissue specimens, 10-fold dilutions were prepared wherein samples were spiked to a
finalconcentrationof6.6to2.6log10 copies/ml.Foursamplesofeachspecimentypewere
testedateachconcentration.Theconcentrationfortissuesampleswascalculatedusingthe
volume of media in each sample after the sample was ground. For the urine samples, four
samples were tested at 10-fold dilutions extending from 6.0 log10 to 2.0 log10 copies/ml.
Patient specimens that had previously tested positive are referred to as clinical samples to
differentiatethemfromspikedsamples.
Nucleic acid extraction and assay set-up
For the reference method, 100 µl of each specimen was extracted on the MagNA Pure LC
(Roche, Indianapolis, IN) using the MagNA Pure LC DNA isolation kit with the DNA I
Blood Cell High Performance protocol. The CACM assay was set-up manually using 50 µl
outofthe100µlelution.
For the test methods, 400 µl of specimen was extracted on the QIAsymphony SP
(Qiagen, Germantown, MD) using the Qiagen Virus/Bacteria Midi kit and Pathogen
Complex 400 protocol. Specimens were also extracted using the same kit and the Cell-free
1000protocol,whichextractsfrom1000µlofsample.Foreightnegativetissuespecimens,
there was insufficient volume for extraction using the Cell-free 1000 protocol. The artus
CMV PCR assay (Qiagen, Germantown, MD) was set-up with a custom protocol on the
QIAsymphonyASthatutilizes10µlofthe95µlelution,12.5µlCMVRGMaster,and2.5µl
ofCMVMg-Sol,forafinalreactionvolumeof25µl.
CMV amplification and detection
The CACM reactions utilized non-saturating, end-point PCR targeting the CMV poly-
merase UL54 gene followed by detection via an automated enzyme-linked oligosorbent
assay (ELOSA). The artus CMV RG PCR reactions used a real-time, hydrolysis-probe-
based PCR targeting the CMV Major Immediate Early gene and were run on the RGQ.
The reactions underwent 10 min at 95 ◦C, then 10 cycles of touchdown PCR with the
annealing step starting at 65 ◦C for 30 s and decreasing by 1 ◦C each cycle. Denaturation
was at 95 ◦C for 15 s and extension at 72 ◦C for 20 s. Touchdown PCR was followed by 35
cycles of 95 ◦C for 15 s, 56 ◦C for 30 s, and 72 ◦C for 20 s. Data was collected on the green
andyellowchannels.Afour-pointstandardcurvewasincludedineachrun.Amplification
of an internal control added prior to extraction ensured adequate extraction efficiency
andtheabsenceofinhibitors.TheanalyticalperformanceoftheartusCMVPCRhasbeen
describedpreviously(Waggoneretal.,2012).
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Basic statistical analysis was performed using Excel software (Microsoft, Redmond,
WA). Paired t-tests were performed using GraphPad software (GraphPad, La Jolla, CA).
Shapiro–Wilk tests were performed using SPSS software (IBM, Armonk, NY) to confirm
thenormalityofthedistributionofthedifferencesinthequantifiedCMVviralload.
RESULTS AND DISCUSSION
Bronchoalveolar lavage fluid
Thirty-six BAL specimens originally extracted with the MagNA Pure LC and tested on
the CACM were subsequently analyzed with the artus CMV RG PCR reagents on the
RGQ after automated extraction and assay set-up using the QIAsymphony SP/AS. An
additional 20 negative BAL specimens were spiked with AD-169 and tested using the
QIAsymphony SP/AS/RGQ. The artus reagents demonstrated 100% (33/33) sensitivity
when samples were extracted with either the Cell-free 1000 or Pathogen Complex 400
protocols. This included 13/13 clinical samples and 20/20 spiked samples. Though this
protocol was developed for qualitative testing on non-plasma specimen types, quantified
resultsweregeneratedandexpressedascopies/ml.Theartusassaywaslinearovertherange
of concentrations tested following the extraction of spiked specimens with either protocol
(Figs. 1A and 1B), and no significant difference in the quantitative results was observed
following extraction with either protocol (mean difference 0.05, 95% CI [−0.03 to 0.13],
p = 0.19).
The specificity for the artus reagents with the Cell-free 1000 and Pathogen Complex
400 protocols were 83% (19/23) and 87% (20/23), respectively. One sample was detected
only using the Cell-free 1000 protocol at a very low level (∼23 copies/ml). This specimen
was negative for CMV by viral culture, though the patient had been previously exposed to
CMV (CMV IgG positive). Additionally, there were three discrepant samples obtained
from separate patients that were detected by both the Pathogen Complex 400 and
Cell-free 1000 protocols, but not CACM. One of these patients received a CMV positive
hematopoietic stem celltransplant and had a historyof CMV hepatitis and retinitis. CMV
wasquantitatedinthisBALspecimenat1062copies/mlusingPathogenComplex400and
472copies/mlusingCell-free1000.Therewaslimitedclinicalandlaboratorydataavailable
for the remaining two patients. Only one had CMV serologic testing performed at our
institution (CMV IgG positive) and for both patients concurrent BAL viral cultures were
negative for CMV. Quantitation of CMV DNA in these specimens revealed 112 and 29
copies/mlusingPathogenComplex400and203and36copies/mlusingCell-free1000.
Tissue
Twenty-five previously tested tissue specimens and 20 negative tissue specimens spiked
with AD-169 were analyzed on the QIAsymphony SP/AS/RGQ system. The artus reagents
demonstrated 100% sensitivity for tissue specimens extracted using either the Cell-free
1000 or Pathogen Complex 400 protocols (25/25, including 5/5 clinical samples and
20/20spikedsamples).Thespecificitywas100%followingextractionwitheitherprotocol,
Waggoner and Pinsky (2014), PeerJ, DOI 10.7717/peerj.334 4/10Figure 1 Assay linearity by specimen type using different extraction protocols. Linearity of the artus
CMV RG PCR assay on DNA extracted from negative clinical samples spiked with serial dilutions of
AD-169 using the Cell-free 1000 and Pathogen Complex 400 protocols on the QIAsymphony SP: BAL
samples (A and B), tissue samples (C and D), and urine samples (E and F).
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Pathogen Complex 400, 20/20). Quantitation of spiked tissue specimens using artus
reagents showed good agreement with the expected results following extraction with both
protocols, and the assay was linear over the range of concentrations tested (Figs. 1C and
1D).Nodifferenceinthequantitativeresultsobtainedusingeitherextractionprotocolwas
seenforthetissuesamples(meandifference0.003,95%CI[−0.09to0.1],p = 0.94).
Urine
Twenty-one previously tested urine specimens and 20 negative urine specimens spiked
withAD-169wereanalyzedontheQIAsymphonySP/AS/RGQsystem.PathogenComplex
400 extraction demonstrated 100% sensitivity (21/21, including one clinical sample and
20/20 spiked samples) and 100% specificity (20/20), whereas Cell-free 1000 extraction
showed 86% sensitivity (18/21, including one clinical sample and 17/20 spiked samples)
and100%specificity(20/20).Thethreespikedurinesamplesthattestednegativefollowing
extraction with the Cell-free 1000 protocol had concentrations of 2.0 log10 (two samples)
and 3.0 log10 copies/ml (one sample). Quantitation of the spiked samples extracted with
the Cell-free 1000 protocol revealed poor agreement with the expected values (Fig. 1E).
In contrast, quantitation following Pathogen Complex 400extraction was linear (Fig. 1F).
The concentration of CMV in the urine samples was, on average, 0.55 log10 copies/ml
higher using the Pathogen Complex 400 extraction protocol compared to the Cell-free
1000 (95% CI [0.14 to 0.95], p = 0.01). CT values for the internal control occurred later
following extraction using the Cell-free 1000 protocol (mean, 27.76; standard deviation,
2.27) compared to the Pathogen Complex 400 (mean, 25.08; standard deviation, 0.19;
p < 0.0001).
CMV detection in body fluid and tissue samples is important for the diagnosis of CMV
disease, yet limited comparative data exist in the literature for viral nucleic acid extraction
and PCR protocols in such samples (Chemaly et al., 2004; Fahle & Fischer, 2000; Kotton
et al., 2010). In this study, we used BAL fluid, tissue samples, and urine to evaluate two
DNA extraction protocols utilizing the QIAsymphony SP/AS followed by real-time PCR
with artus CMV PCR reagents on the RGQ. Both protocols showed good agreement with
CACM,thereferencemethod,forBALandtissuespecimens.
Quantitative testing has been reported in the literature for all of these specimen types
(Chemaly et al., 2004; Ganzenmueller et al., 2009; Kearns et al., 2002; Riise et al., 2000;
Westall et al., 2004). However, clinically meaningful thresholds for the quantitative
detection CMV DNA in such specimens have not yet been defined. Even with the use of
acommoncalibratorsuchasthe1stWorldHealthOrganizationInternationalStandardfor
HumanCytomegalovirusforNucleicAcidAmplificationTechniques,significantconcerns
remain regarding sample collection and processing, which cannot be standardized in
a fashion similar to plasma or whole blood collection. Therefore, the testing protocols
described in this study were validated in our laboratory for the qualitative detection of
CMV from non-plasma tissue specimens. Using spiked clinical specimens, quantitative
CMV PCR using artus CMV reagents allowed for comparisons of the efficiency of DNA
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concentrations were selected to reflect those previously reported in the literature, though
reports are scant, particularly for tissue samples (Chemaly et al., 2004; de Vries et al., 2012;
Ganzenmueller et al., 2009; Kearns et al., 2002; Riise et al., 2000; Roblin et al., 2011; Westall
et al., 2004). Following extraction with either protocol, artus CMV PCR was linear over
therangeofconcentrationstestedforBALfluidandtissuesamples,andtheresultsshowed
goodagreementwithexpectedvalues.
In spiked urine samples, the Pathogen Complex 400 protocol proved more sensitive
than the Cell-free 1000, and the results of the artus CMV PCR following extraction with
the Pathogen Complex 400 were also more accurate when compared to the expected
quantitative values. The detection of CMV in urine samples is primarily used for the
diagnosis of congenital infection among newborns (Lanari et al., 2006). Despite the
high viral loads often present in congenital CMV, previous reports using traditional
viral culture methods have missed the diagnosis in symptomatic patients (Nelson et al.,
1995). The severity of possible sequelae and the lack of a range in CMV viral load that
definesincreasedriskofdiseasesupporttheuseofthemostsensitivetesttodetectCMVin
newborns. In addition, an extraction protocol such as Pathogen Complex 400 that allows
for accurate CMV quantitation in urine may be useful in defining quantitative thresholds
forriskstratification.
Based on our results, the Cell-free 1000 extraction protocol is not appropriate for
urine samples as it resulted in false negatives on 3/20 spiked samples. These may have
resulted from the failure of this protocol to remove PCR inhibitors from urine samples.
This conclusion is supported by the finding that internal control CT values in the artus
assayweresignificantlyhigherandshowedgreatervariabilityfollowingextractionwiththe
Cell-free1000protocolcomparedtothePathogenComplex400.Thesetwoprotocolsdiffer
predominantly by the inclusion of a wash step with buffer ATL (containing SDS) in the
Pathogen Complex 400 protocol, and this may have accounted for the improved results in
urine samples. TheCell-free 1000 protocol couldstill be used asthe sole method forCMV
DNAextractioninlaboratoriesthatdonottestforCMVDNAfromurine.
Three BAL samples were positive using the artus CMV PCR with either extraction
protocol but negative by the CACM, and a single sample was positive only after extraction
using the Cell-free 1000 protocol. On further evaluation, these samples appeared to have
low positive results below the limit reported by the CACM. CMV PCR and hybrid capture
assays have been evaluated in BAL samples from lung transplant recipients, though the
clinicalsignificanceoflow-positiveresults,suchasthosewedetectedinthisstudy,remains
unclear(Chemalyetal.,2004;Riiseetal.,2000).Thequantitativeresultsfromthesestudies
have not consistently predicted CMV pneumonitis, however, no patient with a negative
test for CMV had CMV pneumonitis on biopsy (negative predictive value of 100%)
(Chemalyetal.,2004;Riiseetal.,2000).
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Body fluids and tissues are important specimen types for the evaluation of CMV-related
diseases. Reliable detection of CMV DNA in these specimen types depends not only on
the sensitivity of the PCR assay used but also on the extraction protocol employed in the
clinicallaboratory.FurthercomparativestudiesofdifferentextractionprotocolsandDNA
detectionmethodsinbodyfluidsandtissuesareneeded,asprotocolsoptimizedforplasma
orwholebloodcannotalwaysbeappliedtootherspecimentypes.
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